1. Home
  2. CZNC vs ADCT Comparison

CZNC vs ADCT Comparison

Compare CZNC & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Citizens & Northern Corp

CZNC

Citizens & Northern Corp

HOLD

Current Price

$20.89

Market Cap

425.0M

Sector

Finance

ML Signal

HOLD

Logo ADC Therapeutics SA

ADCT

ADC Therapeutics SA

HOLD

Current Price

$3.44

Market Cap

445.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CZNC
ADCT
Founded
1864
2011
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
425.0M
445.2M
IPO Year
2009
2019

Fundamental Metrics

Financial Performance
Metric
CZNC
ADCT
Price
$20.89
$3.44
Analyst Decision
Hold
Strong Buy
Analyst Count
1
4
Target Price
$23.50
$7.75
AVG Volume (30 Days)
26.1K
1.1M
Earning Date
05-12-2026
05-04-2026
Dividend Yield
4.87%
N/A
EPS Growth
7.64
30.86
EPS
0.02
N/A
Revenue
N/A
$81,357,000.00
Revenue This Year
$3.11
N/A
Revenue Next Year
N/A
$66.49
P/E Ratio
$1,052.50
N/A
Revenue Growth
N/A
14.85
52 Week Low
$18.02
$1.35
52 Week High
$24.12
$4.98

Technical Indicators

Market Signals
Indicator
CZNC
ADCT
Relative Strength Index (RSI) 31.91 33.93
Support Level $19.82 $3.40
Resistance Level $22.48 $3.59
Average True Range (ATR) 0.52 0.22
MACD -0.23 -0.04
Stochastic Oscillator 4.71 9.74

Price Performance

Historical Comparison
CZNC
ADCT

About CZNC Citizens & Northern Corp

Citizens & Northern Corp is a community bank operating through its subsidiaries. It provides banking services, including deposit and loan products for personal and commercial customers. The bank also maintains a trust division that provides a wide range of financial services, such as 401(k) plans, retirement planning, estate planning, estate settlements and asset management.

About ADCT ADC Therapeutics SA

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).

Share on Social Networks: